ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Efficacy"

  • 2019 American Transplant Congress

    Your Path to Transplant Education Increases Patients’ Transplant Knowledge, Attitudes, Informed Decision-Making, and Pursuit: An Randomized Controlled Trial

    A. D. Waterman1, Y. Cui2, J. D. Peipert3, J. L. Beaumont2, C. S. Anderson1, A. L. Paiva4, M. L. Robbins4

    1Division of Nephrology, University of California, Los Angeles, Los Angeles, CA, 2Terasaki Research Institute, Los Angeles, CA, 3Department of Medical Social Sciences, Northwestern University, Chicago, IL, 4Department of Psychology, University of Rhode Island, Kingston, RI

    *Purpose: Most kidney transplant (KT) education is “one-size-fits-all” where patients’ unique gaps in knowledge, challenges, and level of readiness to pursue KT and living donor…
  • 2019 American Transplant Congress

    Optimizing Patient Blood Management in Simultaneous Kidney and Pancreas Transplantation

    D. P. Al-Adra, J. Odorico, D. Kaufman, R. Redfield, J. P. Connor

    University of Wisconsin, Madison, WI

    *Purpose: To identify a post-operative hematocrit (Hct) target for patients recovering from simultaneous kidney and pancreas (SPK) transplant and pancreas transplant alone (PTA) that is…
  • 2019 American Transplant Congress

    The Collaborative Improvement and Innovation Network (COIIN): Impact on Deceased Donor Transplant Rates and Offer Acceptance Practices

    A. Wey1, S. Gustafson1, B. Carrico2, J. Foutz2, K. Sisaithong3, M. McBride2, D. Klassen2, D. Klassen2, N. Salkowski1, B. Kasiske1, A. Israni1, J. Snyder1

    1SRTR, Minneapolis, MN, 2OPTN, Richmond, VA, 3OPTN, Minneapolis, MN

    *Purpose: The Organ Procurement and Transplantation Network (OPTN) completed the Collaborative Improvement and Innovation Network (COIIN), a study to increase kidney transplants by reducing risk…
  • 2019 American Transplant Congress

    A Comparison of the BAR, DRM, DRI, sRRI, ET-DRI, D-MELD and SOFT Score to Predict Outcome after Liver Transplantation in the SRTR Database

    J. D. de Boer1, H. Putter2, J. J. Blok1, I. P. Alwayn1, B. Van Hoek3, A. E. Braat1

    1Transplant Center, Leiden University Medical Center, Leiden, Netherlands, 2Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands, 3Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands

    *Purpose: Several risk models have been developed to predict outcome after liver transplantation (LT) in the last decade. This study analyzes the ability of these…
  • 2019 American Transplant Congress

    Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study

    R. Oberbauer1, F. Vincenti1, O. Viklicky1, U. Huynh-Do1, D. Kim1, J. M. Cruzado1, Y. Qazi1, M. S. Kim1, P. Narvekar2, M. P. Hernandez Gutierrez2, P. Bernhardt2, D. Kuypers1

    1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland

    *Purpose: To assess the effect of induction therapy on efficacy and safety outcomes of de novo renal transplant recipients (RTxR) receiving everolimus with reduced calcineurin…
  • 2019 American Transplant Congress

    Improving the Organ Donation Process: Updated

    J. Yeh, M. P. Jarrett, L. Teperman

    Northwell Health, New Hyde Park, NY

    *Purpose: Due to the complexity of care that each ICU patient requires, the bedside nurse may miss the clinical trigger that would indicate an appropriate…
  • 2019 American Transplant Congress

    The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen

    R. Wolff1, A. Nasstrom1, C. Borscheid1, C. Martin1, A. Temelie1, R. Spong2, D. Keys2, T. B. Dunn3

    1School of Pharmacy, MHealth U of MN Medical Center-Fairview, Mpls, MN, 2Medicine, MHealth U of MN Medical Center-Fairview, Mpls, MN, 3Surgery, U of Pennsylvania, Phila, PA

    *Purpose: It is not known if an extended release formulation of tacrolimus (LCPT, Envarsus XR®) can be successfully dosed to achieve an early therapeutic trough…
  • 2018 American Transplant Congress

    Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies

    F. Shihab,1 Y. Qazi,1,2 V. Peddi,1 D. Shaffer,1 D. Kim,1,2 K. McCague,3 D. Patel,3 S. Mulgaonkar.1,2

    1US92 Study Group, Salt Lake City; 2TRANSFORM Study Group, East Hanover; 3Novartis Pharmaceuticals Corporation, East Hanover.

    Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…
  • 2018 American Transplant Congress

    A Novel Combined Formula to Direct Optimal Immunosuppressive Drug Exposure in Renal Transplant Recipients

    O. Pankewycz,1 E. Onan,2 M. Laftavi,1 R. Gruessner,3 H. Smileuski,1 E. Alissandrello,1 A. Gruessner.3

    1Upstate Medical University, Syracuse, NY; 2Cukurova University, Adana, Turkey; 3Downstate Medical University, New York, NY.

    Purpose: The most widely used maintenance immunosuppressive combination after kidney transplantation is tacrolimus (TAC) and mycophenolic acid (MPA). The utility of therapeutic drug monitoring for…
  • 2018 American Transplant Congress

    The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients

    B. Suwelack,1 C. Sommerer,1 D. Dragun,1 O. Witzke,1 C. Hugo,1 N. Kamar,2 P. Merville,2 A. Hauser,1 P. Schenker,1 M. Junge,3 B. Nashan,1 F. Thaiss.1

    1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.

    The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences